Compare Stocks: RAPP, SNTG, BLTE, and LNTH

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLTE Belite Bio	$170.96 +0.4%	$163.39	$68.21 ▼ $200.00	$6.88B	-1.23	201,330 shs	93,895 shs
LNTH Lantheus	$100.55 -0.2%	$101.75	$49.67 ▼ $111.86	$6.56B	-0.03	965,787 shs	1.03 million shs
RAPP Rapport Therapeutics	$40.45 -3.6%	$44.86	$23.75 ▼ $52.93	$1.94B	1.02	285,579 shs	998,056 shs
SNTG Sentage	$1.73 -2.6%	$1.85	$1.58 ▼ $4.08	$4.81M	2.43	5,924 shs	6,238 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLTE Belite Bio	0.00%	-1.63%	+5.57%	+17.00%	+134.19%
LNTH Lantheus	0.00%	+0.30%	+0.31%	-3.24%	+97.78%
RAPP Rapport Therapeutics	0.00%	-7.27%	-15.46%	+8.33%	+53.80%
SNTG Sentage	0.00%	-0.57%	+0.58%	-23.45%	-39.30%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLTE Belite Bio	$170.96 +0.4%	$163.39	$68.21 ▼ $200.00	$6.88B	-1.23	201,330 shs	93,895 shs
LNTH Lantheus	$100.55 -0.2%	$101.75	$49.67 ▼ $111.86	$6.56B	-0.03	965,787 shs	1.03 million shs
RAPP Rapport Therapeutics	$40.45 -3.6%	$44.86	$23.75 ▼ $52.93	$1.94B	1.02	285,579 shs	998,056 shs
SNTG Sentage	$1.73 -2.6%	$1.85	$1.58 ▼ $4.08	$4.81M	2.43	5,924 shs	6,238 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLTE Belite Bio	0.00%	-1.63%	+5.57%	+17.00%	+134.19%
LNTH Lantheus	0.00%	+0.30%	+0.31%	-3.24%	+97.78%
RAPP Rapport Therapeutics	0.00%	-7.27%	-15.46%	+8.33%	+53.80%
SNTG Sentage	0.00%	-0.57%	+0.58%	-23.45%	-39.30%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLTE Belite Bio	2.64	Moderate Buy	$218.73	27.94% Upside
LNTH Lantheus	2.29	Hold	$108.11	7.52% Upside
RAPP Rapport Therapeutics	3.00	Buy	$64.29	58.93% Upside
SNTG Sentage	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest RAPP, SNTG, BLTE, and LNTH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	RAPP Rapport Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$65.00 ➝ $75.00
9/10/2026	LNTH Lantheus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)
9/9/2026	BLTE Belite Bio	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$220.00 ➝ $234.00
9/9/2026	BLTE Belite Bio	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold
9/8/2026	BLTE Belite Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$245.00
9/4/2026	BLTE Belite Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$303.00
9/4/2026	BLTE Belite Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$303.00
9/3/2026	BLTE Belite Bio	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/3/2026	BLTE Belite Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$214.00 ➝ $245.00
8/27/2026	LNTH Lantheus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
8/19/2026	RAPP Rapport Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$65.00

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLTE Belite Bio	N/A	N/A	N/A	N/A	$20.54 per share	N/A
LNTH Lantheus	$1.56B	4.22	$6.38 per share	15.75	$16.43 per share	6.12
RAPP Rapport Therapeutics	N/A	N/A	N/A	N/A	$10.17 per share	N/A
SNTG Sentage	$70K	69.45	N/A	N/A	$2.81 per share	0.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLTE Belite Bio	-$77.61M	-$2.73	N/A	187.87	N/A	N/A	-11.84%	-11.62%	11/9/2026 (Estimated)
LNTH Lantheus	$233.56M	$4.14	24.29	18.42	N/A	17.69%	28.10%	14.35%	11/5/2026 (Estimated)
RAPP Rapport Therapeutics	-$111.48M	-$3.04	N/A	N/A	N/A	N/A	-29.02%	-27.37%	11/5/2026 (Estimated)
SNTG Sentage	-$2.28M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest RAPP, SNTG, BLTE, and LNTH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	BLTE Belite Bio	-$0.73	-$0.54	+$0.19	-$0.70	N/A	N/A
8/6/2026	Q2 2026	LNTH Lantheus	$1.30	$1.55	+$0.25	$1.11	$363.23 million	$388.18 million
8/5/2026	Q2 2026	RAPP Rapport Therapeutics	-$1.12	-$1.19	-$0.07	-$1.19	$2.22 million	N/A
6/30/2026	Q2 2026	BLTE Belite Bio	N/A	-$0.54	N/A	-$0.70	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLTE Belite Bio	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
RAPP Rapport Therapeutics	N/A	N/A	N/A	N/A	N/A
SNTG Sentage	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLTE Belite Bio	N/A	33.56	33.56
LNTH Lantheus	0.43	3.06	2.89
RAPP Rapport Therapeutics	N/A	15.72	15.72
SNTG Sentage	N/A	2.14	2.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLTE Belite Bio	0.53%
LNTH Lantheus	99.06%
RAPP Rapport Therapeutics	N/A
SNTG Sentage	0.05%

Insider Ownership

Company	Insider Ownership
BLTE Belite Bio	13.29%
LNTH Lantheus	1.70%
RAPP Rapport Therapeutics	12.48%
SNTG Sentage	62.36%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLTE Belite Bio	41	40.27 million	34.92 million	Not Optionable
LNTH Lantheus	1,193	65.27 million	64.16 million	Optionable
RAPP Rapport Therapeutics	84	47.98 million	41.99 million	N/A
SNTG Sentage	7	2.81 million	1.06 million	Not Optionable

RAPP, SNTG, BLTE, and LNTH Headlines

Recent News About These Companies

Sentage Holdings Narrows First-Half 2025 Loss Amid Cost Cuts but Cash Balance Declines

December 19, 2025 | tipranks.com

Sentage Holdings Inc trading resumes

September 9, 2025 | msn.com

Sentage Holdings Inc trading halted, volatility trading pause

September 9, 2025 | msn.com

Sentage Holdings Delays Yearly Report Filing

April 30, 2025 | tipranks.com

Why Did Sentage Holdings Inc (SNTG) Stock See -14.08% Plunge in the Last 90 Days?

December 26, 2024 | bovnews.comB

Sentage Holdings Inc. Announces Financial Results for the First Six Months of Fiscal Year 2024

December 17, 2024 | prnewswire.com

Sentage Hldgs (NASDAQ:SNTG) Stock Quotes, Forecast and News Summary

October 7, 2024 | benzinga.com

Sentage Holdings Inc (SNTG) Surges 6.55% Amidst Market Fluctuations

October 2, 2024 | gurufocus.com

Trupanion, CNFinance among financial movers

May 15, 2024 | msn.com

Sentage Holdings Full Year 2023 Earnings: US$0.80 loss per share (vs US$1.08 loss in FY 2022)

April 28, 2024 | finance.yahoo.com

Cleanspark, Digital World Acquisition among financial movers

March 20, 2024 | msn.com

Why Is Sentage (SNTG) Stock Up 86% Today?

January 9, 2024 | investorplace.com

Wall Street Set to Open 2024 Lower Amid Rise in Oil Prices, Ahead of Manufacturing, Construction Data

January 2, 2024 | msn.com

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.05%

December 29, 2023 | msn.com

Why Sentage Holdings Shares Are Trading Lower By 5%; Here Are 20 Stocks Moving Premarket

December 26, 2023 | msn.com

Tesla, Apple And 3 Stocks To Watch Heading Into Tuesday

December 26, 2023 | msn.com

Sentage Hldgs Stock (NASDAQ:SNTG), Guidance and Forecast

December 23, 2023 | benzinga.com

Sentage Hldgs Stock (NASDAQ:SNTG) Dividends: History, Yield and Dates

December 23, 2023 | benzinga.com

Sentage Holdings GAAP EPS of -$0.46, revenue of $0.08M

December 22, 2023 | msn.com

Sentage Holdings Inc. Announces Financial Results for the First Six Months of Fiscal Year 2023

December 22, 2023 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RAPP, SNTG, BLTE, and LNTH Company Descriptions

Belite Bio NASDAQ:BLTE

$170.96 +0.61 (+0.36%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$171.18 +0.22 (+0.13%)

As of 09/18/2026 07:30 PM Eastern

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Lantheus NASDAQ:LNTH

$100.55 -0.25 (-0.25%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$100.27 -0.28 (-0.28%)

As of 09/18/2026 07:30 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Rapport Therapeutics NASDAQ:RAPP

$40.45 -1.50 (-3.58%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$40.48 +0.03 (+0.07%)

As of 09/18/2026 07:30 PM Eastern

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

Sentage NASDAQ:SNTG

$1.73 -0.05 (-2.56%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$1.73 0.00 (0.00%)

As of 09/18/2026 07:44 PM Eastern

Sentage Holdings Inc. provides a range of financial services. The company offers consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China. It also provides consultancy and information technology support services. Sentage Holdings Inc. was incorporated in 2019 and is headquartered in Shanghai, the People's Republic of China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RAPP, SNTG, BLTE, and LNTH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RAPP, SNTG, BLTE, and LNTH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RAPP, SNTG, BLTE, and LNTH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RAPP, SNTG, BLTE, and LNTH Company Descriptions

Belite Bio NASDAQ:BLTE

Lantheus NASDAQ:LNTH

Rapport Therapeutics NASDAQ:RAPP

Sentage NASDAQ:SNTG

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RAPP, SNTG, BLTE, and LNTH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RAPP, SNTG, BLTE, and LNTH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RAPP, SNTG, BLTE, and LNTH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RAPP, SNTG, BLTE, and LNTH Company Descriptions

Belite Bio NASDAQ:BLTE

Lantheus NASDAQ:LNTH

Rapport Therapeutics NASDAQ:RAPP

Sentage NASDAQ:SNTG

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools